{"transactions":[{"id":746344,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:36:12.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":2625,"price":10.73,"value":28166.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10958,"source":{"system":"sec-edgar","filing":"0001808365-26-000004","document":"form4-06082026_080608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000180836526000004/form4-06082026_080608.xml","form_type":"4"}},{"id":748115,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:15:12.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":7433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":7433,"derivative":{"exercise_price":10.5,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":7433},"source":{"system":"sec-edgar","filing":"0001808365-26-000002","document":"form4-06052026_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000180836526000002/form4-06052026_040608.xml","form_type":"4"}},{"id":748114,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:15:12.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":13583,"source":{"system":"sec-edgar","filing":"0001808365-26-000002","document":"form4-06052026_040608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000180836526000002/form4-06052026_040608.xml","form_type":"4"}},{"id":963205,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T21:15:05.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":130494,"price":17.75,"value":2316268.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares tendered and accepted for purchase by the Issuer in a cash tender offer commenced by the Issuer on October 20, 2025. The Issuer announced the final results of the tender offer on November 20, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":102233,"source":{"system":"sec-edgar","filing":"0001808365-25-000005","document":"form4-12182025_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000180836525000005/form4-12182025_041201.xml","form_type":"4"}},{"id":963204,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T21:15:05.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":191527,"price":17.75,"value":3399604.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares tendered and accepted for purchase by the Issuer in a cash tender offer commenced by the Issuer on October 20, 2025. The Issuer announced the final results of the tender offer on November 20, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":150047,"source":{"system":"sec-edgar","filing":"0001808365-25-000005","document":"form4-12182025_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000180836525000005/form4-12182025_041201.xml","form_type":"4"}},{"id":1119804,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:15:23.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10500,"derivative":{"exercise_price":14.82,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001415889-25-015979","document":"form4-06062025_040617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000141588925015979/form4-06062025_040617.xml","form_type":"4"}},{"id":1119803,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:15:23.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":6441,"source":{"system":"sec-edgar","filing":"0001415889-25-015979","document":"form4-06062025_040617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000141588925015979/form4-06062025_040617.xml","form_type":"4"}},{"id":1495235,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T20:15:16.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":46.31,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-015153","document":"form4-06032024_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000141588924015153/form4-06032024_040610.xml","form_type":"4"}},{"id":1862541,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T20:42:59.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":48.79,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-035455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919123035455/doc4.xml","form_type":"4"}},{"id":2049813,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-20T21:32:18.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":1191,"price":20.98,"value":24987.18,"ownership":{"direct":true},"balance_after":1191,"source":{"system":"sec-edgar","filing":"0001209191-23-004279","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919123004279/doc4.xml","form_type":"4"}},{"id":2245009,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-03T20:28:45.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":32.95,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-22-034048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122034048/doc4.xml","form_type":"4"}},{"id":2444333,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":435,"price":59,"value":25665.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":232727,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444332,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":667,"price":59,"value":39353.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":341574,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444331,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":886,"price":58.2,"value":51565.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":233162,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444330,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":1356,"price":58.2,"value":78919.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":342241,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444329,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":271,"price":57.23,"value":15509.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":234048,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444328,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-05","kind":"sale","acquired":false,"shares":419,"price":57.23,"value":23979.37,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":343597,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444327,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":2195,"price":58.86,"value":129197.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":234319,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444326,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":3367,"price":58.86,"value":198181.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":344016,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444325,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":2704,"price":57.99,"value":156804.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":236514,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444324,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":4151,"price":57.99,"value":240716.49,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":347383,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444323,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":1113,"price":56.95,"value":63385.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":239218,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444322,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":1707,"price":56.95,"value":97213.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":351534,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444321,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":1383,"price":56.1,"value":77586.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":240331,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444320,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":2124,"price":56.1,"value":119156.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":353241,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444319,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":524,"price":54.95,"value":28793.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":241714,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444318,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":794,"price":54.95,"value":43630.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":355365,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444317,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":162,"price":59.4,"value":9622.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":242238,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444316,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":249,"price":59.4,"value":14790.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":356159,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444315,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":3412,"price":58.96,"value":201171.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":242400,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444314,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":5236,"price":58.96,"value":308714.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":356408,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444313,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":3318,"price":57.83,"value":191879.94,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":245812,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444312,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":5094,"price":57.83,"value":294586.02,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":361644,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444311,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":2406,"price":56.82,"value":136708.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":249130,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2444310,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T00:14:26.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":3678,"price":56.82,"value":208983.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":366738,"source":{"system":"sec-edgar","filing":"0001209191-22-001990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919122001990/doc4.xml","form_type":"4"}},{"id":2486158,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":90,"price":54.67,"value":4920.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.665 to $54.69 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":251536,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486157,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":138,"price":54.67,"value":7544.46,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.665 to $54.69 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":370416,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486156,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":5705,"price":53.86,"value":307271.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.625 to $54.43 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":251626,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486155,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":8747,"price":53.86,"value":471113.42,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.625 to $54.43 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":370554,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486154,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":4155,"price":53.17,"value":220921.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.61 to $53.605 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":257331,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486153,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":6372,"price":53.17,"value":338799.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.61 to $53.605 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":379301,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486152,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":52,"price":52,"value":2704.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.58 to $52.57 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":261486,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486151,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":79,"price":51.99,"value":4107.21,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.58 to $52.57 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":385673,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486150,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1021,"price":56.27,"value":57451.67,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $57.02 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":261538,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486149,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1566,"price":56.27,"value":88118.82,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $57.02 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":385752,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486148,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":1649,"price":55.71,"value":91865.79,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.055 to $56.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":262559,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486147,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":2528,"price":55.71,"value":140834.88,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.055 to $56.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":387318,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486146,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":3372,"price":54.67,"value":184347.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.055 to $55.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":264208,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486145,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":5168,"price":54.67,"value":282534.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.055 to $55.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":389846,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486144,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":2766,"price":53.48,"value":147925.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $54.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10) and (11)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":267580,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2486143,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:05:19.000Z","date":"2021-12-01","kind":"sale","acquired":false,"shares":4243,"price":53.48,"value":226915.64,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $54.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10) and (11)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":395014,"source":{"system":"sec-edgar","filing":"0001209191-21-067877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121067877/doc4.xml","form_type":"4"}},{"id":2526531,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":2346,"price":42.45,"value":99587.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":270346,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526530,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":3597,"price":42.45,"value":152692.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":399257,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526529,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":3957,"price":41.65,"value":164809.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":272692,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526528,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-03","kind":"sale","acquired":false,"shares":6067,"price":41.65,"value":252690.55,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":402854,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526527,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":991,"price":43.04,"value":42652.64,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":276649,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526526,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":1518,"price":43.04,"value":65334.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":408921,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526525,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":2120,"price":42.1,"value":89252.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":277640,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526524,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":3252,"price":42.1,"value":136909.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":410439,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526523,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":4797,"price":42.43,"value":203536.71,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":279760,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526522,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":7350,"price":42.43,"value":311860.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":413691,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526521,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":4599,"price":41.85,"value":192468.15,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":284557,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2526520,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T23:04:35.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":7057,"price":41.85,"value":295335.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":421041,"source":{"system":"sec-edgar","filing":"0001209191-21-062812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121062812/doc4.xml","form_type":"4"}},{"id":2537404,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-20","kind":"sale","acquired":false,"shares":1463,"price":38.31,"value":56047.53,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.91 to $38.55 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":289156,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537403,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-20","kind":"sale","acquired":false,"shares":2242,"price":38.31,"value":85891.02,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.91 to $38.55 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":428098,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537402,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-20","kind":"sale","acquired":false,"shares":148,"price":37.55,"value":5557.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $37.90 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":290619,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537401,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-20","kind":"sale","acquired":false,"shares":229,"price":37.55,"value":8598.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $37.90 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":430340,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537400,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":460,"price":38.49,"value":17705.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.74 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":290767,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537399,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":704,"price":38.49,"value":27096.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.74 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":430569,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537398,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":1323,"price":38.05,"value":50340.15,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.37 to $38.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":291227,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2537397,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-21T20:29:15.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":2029,"price":38.05,"value":77203.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.37 to $38.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":431273,"source":{"system":"sec-edgar","filing":"0001209191-21-061256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121061256/doc4.xml","form_type":"4"}},{"id":2540665,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":60,"price":38.46,"value":2307.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":292550,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540664,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":92,"price":38.46,"value":3538.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":433302,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540663,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":5382,"price":37.69,"value":202847.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.30 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":292610,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540662,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":8252,"price":37.69,"value":311017.88,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.30 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":433394,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540661,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":60,"price":40.6,"value":2436.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":297992,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540660,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":92,"price":40.6,"value":3735.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":441646,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540659,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":1199,"price":39.44,"value":47288.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.29 to $40.11 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":298052,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540658,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":1839,"price":39.44,"value":72530.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.29 to $40.11 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":441738,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540657,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":1977,"price":38.95,"value":77004.15,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $39.28 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":299251,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540656,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":3031,"price":38.95,"value":118057.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $39.28 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":443577,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540655,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":1730,"price":40.13,"value":69424.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":301228,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2540654,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T00:35:55.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":2653,"price":40.13,"value":106464.89,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":446608,"source":{"system":"sec-edgar","filing":"0001209191-21-060784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121060784/doc4.xml","form_type":"4"}},{"id":2549293,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T00:47:33.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":1033,"price":40.03,"value":41350.99,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.14 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":302958,"source":{"system":"sec-edgar","filing":"0001209191-21-059749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121059749/doc4.xml","form_type":"4"}},{"id":2549292,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T00:47:33.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":1584,"price":40.03,"value":63407.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.14 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":449261,"source":{"system":"sec-edgar","filing":"0001209191-21-059749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121059749/doc4.xml","form_type":"4"}},{"id":2549291,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T00:47:33.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":1479,"price":40.06,"value":59248.74,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.33 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":303991,"source":{"system":"sec-edgar","filing":"0001209191-21-059749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121059749/doc4.xml","form_type":"4"}},{"id":2549290,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T00:47:33.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":2267,"price":40.06,"value":90816.02,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.33 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":450845,"source":{"system":"sec-edgar","filing":"0001209191-21-059749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121059749/doc4.xml","form_type":"4"}},{"id":2549289,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T00:47:33.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":2496,"price":40.16,"value":100239.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":305470,"source":{"system":"sec-edgar","filing":"0001209191-21-059749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121059749/doc4.xml","form_type":"4"}},{"id":2549288,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T00:47:33.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":3827,"price":40.16,"value":153692.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":453112,"source":{"system":"sec-edgar","filing":"0001209191-21-059749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121059749/doc4.xml","form_type":"4"}},{"id":2556743,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-29T20:39:15.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":6532,"price":42.29,"value":276238.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.93 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":307966,"source":{"system":"sec-edgar","filing":"0001209191-21-058061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121058061/doc4.xml","form_type":"4"}},{"id":2556742,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-29T20:39:15.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":10018,"price":42.29,"value":423661.22,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.93 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":456939,"source":{"system":"sec-edgar","filing":"0001209191-21-058061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121058061/doc4.xml","form_type":"4"}},{"id":2556741,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-29T20:39:15.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":13233,"price":41.52,"value":549434.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.96 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":314498,"source":{"system":"sec-edgar","filing":"0001209191-21-058061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121058061/doc4.xml","form_type":"4"}},{"id":2556740,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-29T20:39:15.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":20292,"price":41.52,"value":842523.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.96 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":466957,"source":{"system":"sec-edgar","filing":"0001209191-21-058061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121058061/doc4.xml","form_type":"4"}},{"id":2556739,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-29T20:39:15.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":17854,"price":40.51,"value":723265.54,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":327731,"source":{"system":"sec-edgar","filing":"0001209191-21-058061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121058061/doc4.xml","form_type":"4"}},{"id":2556738,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-29T20:39:15.000Z","date":"2021-09-27","kind":"sale","acquired":false,"shares":27373,"price":40.51,"value":1108880.23,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":487249,"source":{"system":"sec-edgar","filing":"0001209191-21-058061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121058061/doc4.xml","form_type":"4"}},{"id":2641503,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T22:02:40.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":3776,"price":41.72,"value":157534.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.00 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":345585,"source":{"system":"sec-edgar","filing":"0001209191-21-045620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121045620/doc4.xml","form_type":"4"}},{"id":2641502,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T22:02:40.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":5789,"price":41.72,"value":241517.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.00 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":514622,"source":{"system":"sec-edgar","filing":"0001209191-21-045620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121045620/doc4.xml","form_type":"4"}},{"id":2641501,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T22:02:40.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":5626,"price":41.08,"value":231116.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $41.50 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":349361,"source":{"system":"sec-edgar","filing":"0001209191-21-045620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121045620/doc4.xml","form_type":"4"}},{"id":2641500,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T22:02:40.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":8627,"price":41.08,"value":354397.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $41.50 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Partners Innovation Fund, LLC (\"PIF I\"). Partners Innovation Fund, LLC (\"Partners GP I\") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I."}],"balance_after":520411,"source":{"system":"sec-edgar","filing":"0001209191-21-045620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121045620/doc4.xml","form_type":"4"}},{"id":2641499,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40517,"kind":"person","name":"Knowles Julius","position":1,"cik":"0001808365","reported_name":"Knowles Julius","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T22:02:40.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":30,"price":42.75,"value":1282.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Partners Innovation Fund II, L.P. (\"PIF II\"). Partners Innovation Fund II, LLC (\"Partners GP II\") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II."}],"balance_after":354987,"source":{"system":"sec-edgar","filing":"0001209191-21-045620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808365/000120919121045620/doc4.xml","form_type":"4"}}],"next_cursor":"2021-07-06T22:02:40.000000Z,2641499"}